Literature DB >> 21915627

Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites.

Dulcilene M Oliveira1, Mariana Amália F Costa, Miguel A Chavez-Fumagalli, Diogo G Valadares, Mariana C Duarte, Lourena E Costa, Vivian T Martins, Rosângela F Gomes, Maria N Melo, Manuel Soto, Carlos Alberto P Tavares, Eduardo Antonio F Coelho.   

Abstract

Experimental vaccines to protect against visceral leishmaniasis (VL) have been developed by using BALB/c mice infected with a large (10⁷ to 10⁸) inoculum of parasites. Remarkably, prior literature has reported that the poor protection observed is mainly due to the high susceptibility of this strain. To determine factors inherent to mice that might abrogate vaccine-induced efficacy, the present research sought to investigate the impact of the administration of different infective inoculums of Leishmania chagasi (syn. L. infantum) in BALB/c mice, evaluating subcutaneous and intravenous routes of administration as well as parasitological and immunological parameters over different periods of time. This study shows that the injection of a highly infective inoculum in mice, through both subcutaneous and intravenous routes, results in a sustained infection. The mice developed a high parasite load in the liver; however, these values diminished over time. This result did not corroborate with the parasite load in the bone marrow and brain and proved to be expressively different in the spleen and draining lymph nodes, where the values increased over time. Mice infected with a low dose of parasites (10³) showed a certain resistance against infection, based mainly on the IFN-γ and oxide nitric production. Considering all the elements, it could be concluded that the models employing high doses (10⁷) of L. chagasi in BALB/c mice can bring about an imbalance in the animals' immune response, thus allowing for the development of the disease at the expense of efficacy within the vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21915627     DOI: 10.1007/s00436-011-2628-5

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  45 in total

1.  Immunohistological features of visceral leishmaniasis in BALB/c mice.

Authors:  J Carrión; A Nieto; S Iborra; V Iniesta; M Soto; C Folgueira; D R Abanades; J M Requena; C Alonso
Journal:  Parasite Immunol       Date:  2006-05       Impact factor: 2.280

2.  In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease.

Authors:  H Himmelrich; P Launois; I Maillard; T Biedermann; F Tacchini-Cottier; R M Locksley; M Röcken; J A Louis
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

3.  The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.

Authors:  J Lehmann; K H Enssle; I Lehmann; A Emmendörfer; M L Lohmann-Matthes
Journal:  J Interferon Cytokine Res       Date:  2000-01       Impact factor: 2.607

Review 4.  Recent advances in vaccines for leishmaniasis.

Authors:  Jose M Requena; Salvador Iborra; Javier Carrión; Carlos Alonso; Manuel Soto
Journal:  Expert Opin Biol Ther       Date:  2004-09       Impact factor: 4.388

5.  Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity.

Authors:  H W Murray; K E Squires; C D Miralles; M Y Stoeckle; A M Granger; A Granelli-Piperno; C Bogdan
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

6.  Influence of the inoculation route in BALB/c mice infected by Leishmania infantum.

Authors:  Nuno Rolão; Cláudia Melo; Lenea Campino
Journal:  Acta Trop       Date:  2004-03       Impact factor: 3.112

7.  Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Fernando Aécio Amorim Carvalho; Karina Figueiredo Chaves; Kadima Nayara Teixeira; Rafaela Chitarra Rodrigues; Hugues Charest; Greg Matlashewski; Ricardo Tostes Gazzinelli; Ana Paula Fernandes
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

8.  Protein-energy malnutrition decreases immune response to Leishmania chagasi vaccine in BALB/c mice.

Authors:  G Malafaia; T D Serafim; M E Silva; M L Pedrosa; S A Rezende
Journal:  Parasite Immunol       Date:  2009-01       Impact factor: 2.280

9.  Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13.

Authors:  Rajatava Basu; Suniti Bhaumik; Arun Kumar Haldar; Kshudiram Naskar; Tripti De; Syamal Kumar Dana; Peter Walden; Syamal Roy
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

10.  Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.

Authors:  L C Afonso; P Scott
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

View more
  18 in total

1.  Site-dependent recruitment of inflammatory cells determines the effective dose of Leishmania major.

Authors:  Flavia L Ribeiro-Gomes; Eric Henrique Roma; Matheus B H Carneiro; Nicole A Doria; David L Sacks; Nathan C Peters
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

2.  Leishmania tropica: suggestive evidences for the effect of infectious dose on pathogenicity and immunogenicity in an experimental model.

Authors:  Mosayeb Rostamian; Davood Jafari; Maryam Abolghazi; Hadiseh Farahani; Hamid M Niknam
Journal:  Parasitol Res       Date:  2018-07-05       Impact factor: 2.289

3.  Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.

Authors:  Kevin W Bruhn; Ron Birnbaum; Jacquelyn Haskell; Veena Vanchinathan; Stephanie Greger; Rupa Narayan; Pei-Lin Chang; Thu Anh Tran; Suzanne M Hickerson; Stephen M Beverley; Mary E Wilson; Noah Craft
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

4.  Functionalized 1,2,3-triazolium salts as potential agents against visceral leishmaniasis.

Authors:  Ayla das Chagas Almeida; Raíssa Soares Meinel; Yasmim Lopes Leal; Thiago P Silva; Nícolas Glanzmann; Débora Vasconcelos Costa Mendonça; Luísa Perin; Edézio Ferreira Cunha-Júnior; Eduardo A F Coelho; Rossana C N Melo; Adilson David da Silva; Elaine Soares Coimbra
Journal:  Parasitol Res       Date:  2022-02-16       Impact factor: 2.289

5.  An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.

Authors:  Letícia Martins Dos Reis Lage; José Mário Barichello; Daniela Pagliara Lage; Débora Vasconcelos Costa Mendonça; Ana Maria Ravena Severino Carvalho; Marcella Rezende Rodrigues; Daniel Menezes-Souza; Bruno Mendes Roatt; Ricardo José Alves; Carlos Alberto Pereira Tavares; Eduardo Antonio Ferraz Coelho; Mariana Costa Duarte
Journal:  Parasitol Res       Date:  2016-07-01       Impact factor: 2.289

Review 6.  Immunoregulation in human American leishmaniasis: balancing pathology and protection.

Authors:  K J Gollob; A G Viana; W O Dutra
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

7.  Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.

Authors:  Paula S Lage; Miguel A Chávez-Fumagalli; Juliana T Mesquita; Laís M Mata; Simone O A Fernandes; Valbert N Cardoso; Manuel Soto; Carlos A P Tavares; João P V Leite; Andre G Tempone; Eduardo A F Coelho
Journal:  Parasitol Res       Date:  2015-09-07       Impact factor: 2.289

8.  Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis.

Authors:  Joana Cunha; Eugenia Carrillo; Carmen Sánchez; Israel Cruz; Javier Moreno; Anabela Cordeiro-da-Silva
Journal:  Parasit Vectors       Date:  2013-04-26       Impact factor: 3.876

9.  Therapeutic immunization with radio-attenuated Leishmania parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis.

Authors:  Sanchita Datta; Madhumita Manna; Supriya Khanra; Moumita Ghosh; Radhaballav Bhar; Anindita Chakraborty; Syamal Roy
Journal:  Parasitol Res       Date:  2012-03-23       Impact factor: 2.383

10.  Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.

Authors:  Vivian T Martins; Miguel A Chávez-Fumagalli; Lourena E Costa; Adriana M C Canavaci; Adriana M C C Martins; Paula S Lage; Daniela P Lage; Mariana C Duarte; Diogo G Valadares; Rubens D M Magalhães; Tatiana G Ribeiro; Ronaldo A P Nagem; Wanderson D Darocha; Wiliam C B Régis; Manuel Soto; Eduardo A F Coelho; Ana Paula Fernandes; Carlos A P Tavares
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.